Clinical Trial Update: Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on empagliflozin for cardioprotection in cancer patients receiving doxorubicin across phase 2 and phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Ain Shams University | Conditions: Cancer | Phase 2, Phase 3 | Status: UNKNOWN